LaNova Medicines is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) and bispecific antibodies targeting unmet needs in tumor immunology and the tumor microenvironment. Their proprietary platforms enhance the discovery and optimization of therapeutic antibodies, addressing the challenges of treating various solid tumors and hematological malignancies.
Funding
Funding not disclosed
Founders
Product
Problem
The tumor microenvironment presents significant challenges for cancer treatment, including limited drug penetration, immune suppression, and the development of resistance. Traditional antibody therapies often fail to effectively target tumor cells and modulate the immune response within this complex environment, leading to suboptimal outcomes for patients with solid tumors and hematological malignancies.
Solution
LaNova Medicines is developing antibody-drug conjugates (ADCs) and bispecific antibodies designed to overcome the limitations of conventional cancer therapies by targeting unmet needs in tumor immunology and the tumor microenvironment. LaNova's proprietary LX-TAb™ antibody discovery platform enables the identification of antibodies against difficult targets such as GPCRs and multi-pass transmembrane proteins. The LX-ADC™ platform facilitates the creation of next-generation ADCs with optimized targeting strategies, antibody designs, and linker-payload combinations. The LX-TDuo™ platform is used to generate multi-specific antibodies that can efficiently activate immune cells within the tumor microenvironment, promoting cancer cell killing and inhibiting tumor growth.
Target Audience
LaNova Medicines primarily targets patients with solid tumors and hematological malignancies who are not adequately served by existing therapies, as well as pharmaceutical companies seeking innovative oncology assets for licensing or co-development.
Features
- LX-TAb™ antibody discovery platform for efficient identification, screening, and optimization of antibodies against challenging targets
- LX-ADC™ platform for generating next-generation ADCs with tailored targeting and payload delivery
- LX-TDuo™ platform for developing multi-specific antibodies that enhance immune cell activation in the tumor microenvironment
- Pipeline of clinical-stage assets, including LM-302 (anti-Claudin18.2 ADC), LM-108 (anti-CCR8 mAb), and LM-101 (anti-SIRPα mAb)
- Preclinical programs targeting NaPi2b, CDH17, CEACAM5, GPC3, LIV-1 and FRα with ADC modalities
- Focus on solid tumors and hematological malignancies with high unmet need